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OBJECTIVE — Insulin glargine (Lantus) is an extended-action insulin analog with greater
stability and duration of action than regular human insulin. The long duration of action and
decreased incidence of hypoglycemia provide potential advantages for its use in pregnancy.
However, the placental pharmacokinetics of insulin glargine have not been studied. Therefore,
theobjectiveofthisstudywastodeterminewhetherinsulinglarginecrossesthehumanplacenta
using the human perfused placental lobule technique.
RESEARCH DESIGN AND METHODS — Placentae were obtained with informed con-
sent after elective cesarean section delivery of noncomplicated term pregnancies. Insulin
glargine, at a therapeutic concentration of 150 pmol/l (20 U/ml) was added to the maternal
circulation. Additional experiments were carried out at insulin glargine concentrations 1,000-
foldhigherthantherapeuticlevels(150,225,and300nmol/l).Asubsequentperfusionforwhich
the maternal circuit remained open and insulin glargine was continuously infused at 150 pmol/l
was completed for further conﬁrmation of ﬁndings. The appearance of insulin glargine in the
fetal circulation was analyzed by a chemiluminescence immunoassay.
RESULTS — Resultsfromperfusionscarriedoutattherapeuticconcentrations(150pmol/l)of
insulin glargine showed no detectable insulin glargine in the fetal circuit. After perfusion with
very high insulin glargine concentrations of 150, 225, and 300 nmol/l, the rate of transfer
remained low at 0.079  0.01, 0.14, and 0.064 pmol   min
1   g tissue
1, respectively.
CONCLUSIONS — Insulin glargine, when used at therapeutic concentrations, is not likely
to cross the placenta.
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S
everal new long-acting insulin ana-
logs, such as glargine and detemir,
are currently available for the treat-
ment of diabetes. These long-acting insu-
lins have the advantage of a very long
elimination half-life (24 h), avoiding a
peak in insulin concentrations (1,2). The
absence of a peak with the use of these
insulin analogs has led to decreased inci-
dence of symptomatic, overall, and noc-
turnalhypoglycemiainpatientswithtype
1 diabetes (3). In addition, these analogs
are increasingly being used in patients
with type 2 diabetes, for whom they pro-
vide improved glycemic control and re-
duced hypoglycemia (4). With their
increaseduse,morewomenwithdiabetes
may ﬁnd themselves pregnant while tak-
ing these insulins or ﬁnd they are taking
these insulins while planning a preg-
nancy. Such insulins may be particularly
useful in pregnancy because tight glyce-
mic control during gestation decreases
the risk of maternal and fetal complica-
tions (5–10) and attenuates their severity
(9). Studies have shown, however, that
severe hypoglycemia is often a conse-
quence of attempts to achieve tight glyce-
mic control in pregnancy (11). Use of
these insulin analogs would help patients
achieve excellent glycemic control with-
out the risk of maternal hypoglycemia.
Insulin glargine (Lantus; Aventis
Pharmaceuticals, Bridgewater, NJ) is a
long-acting insulin analog that differs
from regular human insulin by the addi-
tion of two molecules of arginine to the
COOH terminus of the -chain and the
replacement of aspartic acid with glycine
inpositionA21.Thesemolecularchanges
cause the drug to precipitate upon subcu-
taneous injection, increasing stability and
duration of action (12).
It is believed that insulin does not
cross the placental barrier because of its
large molecular size. However, beef/pork
insulin has been shown to cross the
placenta via the formation of insulin-
antibody complexes, leading to fetal mac-
rosomia despite excellent glycemic
control(13).Whereasinsulinuptakeinto
cellularcompartmentsismainlybyrecep-
tor-mediated endocytosis, there are other
mechanisms in place that may allow its
transfer across biological membranes,
such as pinocytosis and the involvement
of membrane transporters (14). The pos-
sible consequences of transplacental
transferofinsulinanalogs,suchasinsulin
glargine,includeteratogenicity,immuno-
genicity, and mitogenicity. Speciﬁcally,
structural modiﬁcations to insulin have
been shown to cause altered afﬁnity for
the insulin and IGF-1 receptor (15). Al-
though the evidence to date is conﬂicting
(16), one study demonstrated that
glargine has a six- to eightfold increased
afﬁnity for the IGF-1 receptor in the os-
teosarcoma cell line Saos/B10 (15). Con-
cern exists that such growth-promoting
properties may lead to increased fetal
growth and other mitogenic effects
shouldinsulincrosstheplacenta.Itiswell
known that excellent glucose control
throughout pregnancy while minimizing
maternalhypoglycemiaisessentialforthe
safe and effective treatment of women
with diabetes in pregnancy. Conse-
quently, there is a need to address the is-
sues of fetal exposure and safety with the
introduction of new and potentially ben-
eﬁcial insulin analogs, such as insulin
glargine, for use in pregnancy. Although
therearesomecasereportsandcaseseries
describing patients who have gone
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the
1Division of Clinical Pharmacology and Toxicology, the Hospital for Sick Children, Toronto,
Ontario, Canada; the
2Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario,
Canada; the
3Division of Endocrinology, Mount Sinai Hospital, Department of Medicine, University of
Toronto, Toronto, Ontario, Canada; and the
4Department of Laboratory Medicine and Pathobiology,
University of Toronto, Toronto, Ontario, Canada.
Corresponding author: Gideon Koren, gkoren@sickkids.ca.
Received 8 June 2009 and accepted 14 September 2009. Published ahead of print at http://care.
diabetesjournals.org on 6 October 2009. DOI: 10.2337/dc09-1045.
© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
ORIGINAL ARTICLE
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 1, JANUARY 2010 29through a pregnancy using glargine (17–
20), there are no studies to date that have
looked at the placental pharmacokinetics
of glargine. The objective of the present
study was to examine whether insulin
glargine crosses the placenta into the fetal
circulation using the ex vivo technique of
human placental lobule perfusion.
RESEARCH DESIGN AND
METHODS
In vitro perfusion of human
placental cotyledon
Placentae were obtained with informed
consent after elective cesarean section de-
livery of noncomplicated term pregnan-
cies. The placentae were transported to
the laboratory in heparinized ice-cold
PBS. Within 30 min of delivery, maternal
and fetal circulations were established in-
dependently to a peripheral lobule (21).
The fetal and maternal perfusates
were maintained at 37°C and consisted of
heparin (2,000 units/l), kanamycin (100
mg/l), glucose (1.0 g/l), and 40,000 mo-
lecular weight dextran (7.5 g/l maternal;
30 g/l fetal). Antipyrine (1 mmol/l) was
added to the maternal perfusate for deter-
mination of tissue viability.
A single perfusion experiment con-
sisted of a 1-h closed control period fol-
lowed by a 3-h closed experimental
period and a ﬁnal 1-h postcontrol period.
During the control and experimental pe-
riods, the perfusates were maintained at
physiological pH by the addition of small
volumes of sodium bicarbonate and hy-
drochloric acid. The maternal perfusate
was equilibrated with 95% oxygen and
5% nitrogen, and the fetal perfusate was
equilibrated with 5% oxygen and 95%
nitrogen.
Preexperimental control period
The fetal and maternal circulations were
maintained until residual blood was
clearedoutofthevessels.Atthispointthe
maternal and fetal circuits were closed
and the perfusates were recirculated. Ma-
ternal and fetal samples were taken every
15 min to analyze glucose and oxygen
consumption and lactate production to
conﬁrm tissue viability. The integrity of
the placenta was also analyzed by moni-
toring fetal perfusion pressure and fetal
reservoir volume. The perfusion was ter-
minated if there was a loss in fetal reser-
voir volume greater than 3 ml/h. In
addition, the rate of human chorionic go-
nadotropin secretion was determined
from a concentration-time plot as an ad-
ditional marker of physical integrity. Be-
fore the experimental period was begun,
the perfusates in the fetal and maternal
reservoirs were replaced with fresh me-
dia, and the circulations were closed and
recirculated.
Experimental period
In a closed-circuit experiment, insulin
glargine was added at a therapeutic con-
centration of 150 pmol/l (20 U/ml) to
the maternal circulations (n  4) (22).
Additional closed-circuit experiments
(n  4) were also performed at insulin
glargineconcentrations1,000-foldhigher
than therapeutic levels (150, 225, and
300 nmol/l). A subsequent perfusion in
whichthematernalcircuitremainedopen
and insulin glargine was continuously in-
fused at 150 pmol/l was completed for
further conﬁrmation of ﬁndings. Samples
(2 ml) were drawn from the maternal and
fetal reservoirs every 10 min for the ﬁrst
half-hour and every half-hour thereafter
forthemeasurementofinsulinconcentra-
tions as well as for the measurement of
antipyrine, glucose consumption, and
lactate production. Additional samples
weretakenformonitoringofpH,PO2,and
PCO2usingabloodgasanalyzer(ABL625;
Radiometer, Copenhagen, Denmark).
Postexperimental control period
The perfusates in the fetal and maternal
reservoirs were replaced with fresh me-
dia,andbothcirculationswereclosedand
recirculated for the ﬁnal 1-h control pe-
riod. Samples were taken from the fetal
and maternal reservoirs every 15 min for
analysis of glucose and oxygen consump-
tionandlactateproductiontoconﬁrmtis-
sue viability. In addition, the integrity of
the placenta was also analyzed by moni-
toring fetal perfusion pressure and fetal
reservoir volume as in the precontrol and
experimental periods.
Sample analysis
Perfusate samples were kept at 80°C
untiltheywereanalyzed.Glucoseandlac-
tate concentrations, as well as samples
taken for monitoring of pH, PO2, and
PCO2, throughout the perfusion were an-
alyzed simultaneously using a blood gas
analyzer (ABL 625).
Insulin in the maternal and fetal per-
fusatesampleswasmeasuredusingaone-
step chemiluminescent immunoassay
(Architecti2000analyzer;AbbottLabora-
tories)thathasbeenshowntohaveahigh
degree of cross-reactivity with insulin
glargine (83–105%) (23). Standard
curves were prepared for insulin glargine
in perfusate and used to calculate insulin
levelsafteranalysis.Thedetectionlimitof
this method is 0.5 U/ml (23).
RESULTS— ThemeanmassSEMof
theperfusedcotyledonswas12.63.2g.
The fetal arterial pressure remained con-
stant throughout the control and experi-
mental periods (Table 1). The rate of
placenta glucose and oxygen consump-
Table 2 —Maternal to fetal transport of insulin glargine
Experiment
no.
Maternal
concentration
(pmol/l)
Lobule
weight (g)
Fetal concentration
(pmol/l)
Rate of transfer
(pmol   min
1   g
tissue
1)
1 150 15.17 Below LOQ —
2 150 9.8 Below LOQ —
3 150 12.83 Below LOQ —
4 150 19.51 Below LOQ —
5 150 12.24 Below LOQ —
6 150,000 9.64 802.5 0.069
7 150,000 12.46 906.3 0.09
8 225,000 9.08 1,475.2 0.14
9 300,000 12.94 1,001.9 0.064
LOQ, limit of quantitation.
Table 1 —Placental physical parameters
Parameter Value
Lobule weight (g) 12.6  3.2
Fetal ﬂow rate (ml/min) 1.6  0.1
Maternal ﬂow rate (ml/min) 13.6  3.2
Fetal arterial inﬂow pressure
(mmHg)
Precontrol 39.2  6.9
Experimental 37.4  5.7
Postcontrol 38.9  6.0
Data are means  SD (n  9).
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bolic viability, did not vary signiﬁcantly
betweentheexperimentalandcontrolpe-
riods. Measures of human chorionic go-
nadotropin remained stable throughout
the perfusions and indicated a preferen-
tial secretion into the maternal compart-
ment.Lactateproductionwasmaintained
throughout the perfusions. The rates of
antiypyrine disappearance from the ma-
ternalcircuitandappearanceintothefetal
circuitwereindicativeofanoptimalover-
lap between the maternal and fetal
circulations.
Results from the 3-h perfusions per-
formed at maternal therapeutic concen-
trations (150 pmol/l) of insulin glargine
showedadeclineininsulinconcentration
from the maternal circuit over time with
no detectable insulin glargine in the fetal
circuit(Table2,Fig.1).Athigherconcen-
trations of insulin glargine (1,000-fold),
there was an observed decrease in mater-
nal insulin glargine concentrations and
a detectable accumulation of insulin
glargine in the fetal circuit over the 3-h
perfusions(Figs.2and3).However,even
at the excessive concentrations of 150,
225, and 300 nmol/l, the rate of transfer
to the fetal circulation remained low
(0.079  0.01, 0.14, and 0.064 pmol  
min
1   g tissue
1, respectively) (Table
2). A ﬁnal perfusion was performed us-
ing an open maternal circuit with con-
tinuous insulin glargine infusion.
Concentrations were maintained in the
maternal compartment at 137  11.8
pmol/l throughout the 180-min perfu-
sion. Levels of glargine were not detect-
able in the fetal compartment despite
continuous infusion in the maternal
compartment (Fig. 1).
CONCLUSIONS — Our results ob-
tainedfromperfusionscarriedoutatther-
apeutic insulin glargine concentrations
suggest that insulin glargine does not
cross the human placenta to a measurable
extent. Transport across the placenta was
demonstrated at concentrations 1,000-
fold higher than therapeutic levels. Even
at these very high levels, there was a 100-
fold difference in the rate of disappear-
ancefromthematernalcompartmentand
the rate of appearance in the fetal com-
partment.Thisdifferencebetweeninsulin
uptake and insulin transferred to the fetal
compartment probably corresponds to
the clearance of insulin by placental tis-
sue. These data suggest that the placenta
is able to sequester and/or metabolize in-
sulin glargine at concentrations up to
1,000-fold higher than therapeutic levels,
thereby limiting its entry into the fetal
compartment. The limited transfer of in-
sulin glargine across the placenta is sup-
ported by previous research ﬁndings.
Althoughtheliverandkidneyarethema-
jor sites of insulin clearance, the placenta
has been shown to possess receptors for
insulin as well as a capacity for rapid deg-
radation by insulin-degrading enzymes
(24). The insulin receptors have been lo-
cated on the syncytiotrophoblast mem-
brane of the placenta where they interact
with the maternal circulation (24). The
mechanism of clearance by the placenta
most likely involves insulin binding to its
receptor, internalization, and degrada-
tion. However, at very high concentra-
tions, it has been suggested that non–
receptor-mediated processes, such as
pinocytosis,mayalsobeinvolvedininsu-
lin transport across cell membranes in
other tissues (14).
Inthecurrentstudy,wechoseinsulin
glargine levels of 150 pmol/l (20 U/ml)
to mimic typical therapeutic levels
achieved and maintained after adminis-
tration of a single dose of insulin glargine
given by subcutaneous injection (0.3
U/kg)(22).Levelsofinsulinglarginehave
been shown to remain relatively stable
(13–21 U/ml) after subcutaneous injec-
tion (25). Therefore, the results obtained
from perfusions completed at concentra-
tions of 150 pmol/l (20 U/ml) are clini-
cally relevant in showing no placental
transfer.Resultsobtainedfromperfusions
with excessive levels of insulin glargine
(150–300 nmol/l) are important in terms
of determining the capacity of the pla-
Figure 1—Maternal and fetal insulin concentrations during 3-h perfusions in the presence of
therapeuticlevels(150pmol/l)ofinsulinglargine(n5). ,maternalopencircuit;f,maternal
closed circuit; F, fetal.
Figure2—Disappearanceofinsulinfromthematernalcompartmentover180minofperfusionin
the presence of insulin glargine concentrations 1,000-fold greater than therapeutic (150–300
nmol/l) (n  4). f, maternal reservoir concentration 150 nmol/l; F, maternal reservoir concen-
tration 300 nmol/l; Œ, maternal reservoir concentration 150 nmol/l;   , maternal reservoir con-
centration 225 nmol/l.
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therapeutic levels; however, these levels
would not occur in the clinical setting.
The use of the human placental per-
fusion model has its limitations in that it
only allows for the study of transport in
termplacenta.Therefore,ourconclusions
regarding the placental transfer of insulin
glargine cannot be directly extrapolated
to ﬁrst-trimester use. In addition, our
studies were performed using placentae
from healthy term pregnancies. Placentae
of diabetic mothers, particularly those
with poorly controlled diabetes, may ex-
hibit structural or physiological abnor-
malities; however, the consequence of
these abnormalities on the transfer of reg-
ular human insulin or insulin glargine is
not known. Furthermore, these studies
wereperformedonplacentaedeliveredby
cesareansection.Duringactiveprolonged
labor, the mixing of fetal and maternal
bloodcanresultinfetalexposuretodrugs
circulating in maternal blood. Despite
these limitations, the perfusion model is
unparalleled by any other in vitro pla-
cental preparations for the study of
transplacental transfer of drugs in preg-
nancy. This model most closely resem-
bles the in vivo situation, without the
ethical dilemma with clinical studies in
pregnancy or the confounding effects
of maternal metabolism. Importantly,
there are wide differences in placental
structure and function in other mam-
mals, making the ex vivo use of human
placenta ideal.
The structural modiﬁcations to insu-
lin glargine allow a smooth action proﬁle
over24h,whichmimicsphysiologicalin-
sulin secretion typically seen in nondia-
betic patients (12). The peakless activity
of insulin glargine decreases the risk of
hypoglycemia in nonpregnant patients
and for this reason is particularly attrac-
tive for use in pregnancy. Although there
have been few reports on the safety of in-
sulin glargine in pregnancy, several case
series and small case-control studies have
been reported (17–20). The largest was a
case series of 115 women with type 1 di-
abetes who took glargine during preg-
nancy (17). There were no “unexpected”
adverseevents.Asmallcase-controlstudy
of 15 women who took glargine and an
equalnumberwhotookNPHthroughout
pregnancy did not show a signiﬁcant dif-
ference in any maternal or fetal outcomes
(18). Although no randomized clinical
trials of insulin glargine use during preg-
nancy are currently available, data ob-
tained from these case-control studies
and case series further support the ﬁnd-
ings demonstrated by our placental per-
fusion studies, suggesting that insulin
glargine may be safe for use in pregnancy.
In summary, when used at therapeu-
tic concentrations, insulin glargine is not
likely to cross the placenta. Our results
indicate wide capacity of the human pla-
centa to block insulin glargine transfer to
the fetal compartment.
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